Stock listing
NASDAQ:ENGN enGene Therapeutics Inc. Stock
Home listing (NASDAQ) of enGene Therapeutics Inc.
Follow enGene Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ENGN
$1.74 USD -0.11 (-5.9%)
Close on Nov 20, 2026
- Day range
- $1.69 – $1.80 USDNov 20, 2026
- Volume
- 556,716 sharesNov 20, 2026
- Market cap
- $116.6M USDAt the close on Nov 20, 2026 · price × 67.02M shares outstanding
- 52-week range
- $1.40 – $12.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.08M USDMedian day 708,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ENGN · Home | $1.74 USD | -0.11 (-5.9%) | 556,716 | $1.75 | $1.80 | $1.685 | $1.85 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENGN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.74 | -0.11 | -5.9% | $1.75 | $1.80 | $1.685 | 556,716 | |
| $1.85 | +0.13 | +7.6% | $1.71 | $1.95 | $1.654 | 2,805,866 | |
| $1.72 | -0.17 | -9.0% | $1.89 | $1.95 | $1.675 | 1,640,992 | |
| $1.89 | -0.52 | -21.6% | $2.32 | $2.356 | $1.88 | 1,994,847 | |
| $2.41 | +0.13 | +5.7% | $2.41 | $2.51 | $2.17 | 3,721,293 | |
| $2.28 | +0.48 | +26.7% | $1.93 | $2.35 | $1.90 | 11,909,681 | |
| $1.80 | +0.13 | +7.8% | $1.70 | $1.81 | $1.63 | 2,765,800 | |
| $1.67 | -0.10 | -5.6% | $1.76 | $1.76 | $1.63 | 741,191 | |
| $1.77 | +0.02 | +1.1% | $1.75 | $1.80 | $1.70 | 848,998 | |
| $1.75 | +0.07 | +4.2% | $1.68 | $1.775 | $1.632 | 1,426,900 | |
| $1.68 | -0.04 | -2.3% | $1.70 | $1.71 | $1.65 | 624,200 | |
| $1.72 | +0.10 | +6.2% | $1.585 | $1.75 | $1.575 | 1,445,500 | |
| $1.62 | +0.17 | +11.7% | $1.47 | $1.63 | $1.45 | 937,100 | |
| $1.45 | -0.08 | -5.2% | $1.55 | $1.55 | $1.45 | 587,200 | |
| $1.53 | 0.00 | 0.0% | $1.53 | $1.55 | $1.46 | 1,197,800 | |
| $1.53 | -0.05 | -3.2% | $1.57 | $1.62 | $1.52 | 690,400 | |
| $1.58 | +0.03 | +1.9% | $1.54 | $1.60 | $1.535 | 997,400 | |
| $1.55 | -0.03 | -1.9% | $1.625 | $1.625 | $1.55 | 365,300 | |
| $1.58 | +0.02 | +1.3% | $1.57 | $1.625 | $1.554 | 657,800 | |
| $1.56 | -0.02 | -1.3% | $1.55 | $1.575 | $1.54 | 730,200 | |
| $1.58 | -0.05 | -3.1% | $1.619 | $1.65 | $1.57 | 554,600 | |
| $1.63 | -0.04 | -2.4% | $1.68 | $1.681 | $1.59 | 1,108,900 | |
| $1.67 | +0.09 | +5.7% | $1.60 | $1.72 | $1.59 | 1,119,600 | |
| $1.58 | -0.09 | -5.4% | $1.66 | $1.70 | $1.58 | 782,000 | |
| $1.67 | -0.04 | -2.3% | $1.73 | $1.749 | $1.65 | 1,156,500 | |
| $1.71 | +0.15 | +9.6% | $1.61 | $1.735 | $1.58 | 1,176,800 | |
| $1.56 | -0.07 | -4.3% | $1.60 | $1.62 | $1.56 | 943,500 | |
| $1.63 | -0.07 | -4.1% | $1.69 | $1.70 | $1.62 | 913,800 | |
| $1.70 | -0.03 | -1.7% | $1.73 | $1.74 | $1.69 | 462,700 | |
| $1.73 | -0.05 | -2.8% | $1.76 | $1.81 | $1.72 | 359,100 | |
| $1.78 | +0.035 | +2.0% | $1.75 | $1.79 | $1.68 | 1,460,600 | |
| $1.745 | -0.055 | -3.1% | $1.80 | $1.859 | $1.74 | 708,300 | |
| $1.80 | -0.07 | -3.7% | $1.87 | $1.87 | $1.80 | 361,700 | |
| $1.87 | -0.07 | -3.6% | $1.94 | $1.94 | $1.785 | 952,900 | |
| $1.94 | -0.04 | -2.0% | $2.00 | $2.02 | $1.93 | 690,100 | |
| $1.98 | -0.02 | -1.0% | $2.01 | $2.01 | $1.96 | 903,000 | |
| $2.00 | +0.05 | +2.6% | $1.965 | $2.02 | $1.93 | 1,280,600 | |
| $1.95 | -0.02 | -1.0% | $1.97 | $1.97 | $1.915 | 393,200 | |
| $1.97 | +0.01 | +0.5% | $1.96 | $1.98 | $1.90 | 332,200 | |
| $1.96 | +0.04 | +2.1% | $1.94 | $1.969 | $1.875 | 1,976,100 | |
| $1.92 | -0.08 | -4.0% | $1.99 | $1.99 | $1.905 | 796,300 | |
| $2.00 | -0.05 | -2.4% | $2.05 | $2.05 | $1.98 | 669,000 | |
| $2.05 | +0.09 | +4.6% | $1.96 | $2.08 | $1.96 | 1,063,800 | |
| $1.96 | +0.05 | +2.6% | $1.92 | $1.97 | $1.90 | 426,300 | |
| $1.91 | 0.00 | 0.0% | $1.92 | $1.93 | $1.89 | 401,000 | |
| $1.91 | 0.00 | 0.0% | $1.90 | $1.92 | $1.88 | 637,500 | |
| $1.91 | +0.02 | +1.1% | $1.90 | $1.915 | $1.88 | 579,300 | |
| $1.89 | +0.02 | +1.1% | $1.87 | $1.90 | $1.845 | 618,700 | |
| $1.87 | +0.07 | +3.9% | $1.80 | $1.88 | $1.80 | 460,500 | |
| $1.80 | +0.03 | +1.7% | $1.80 | $1.83 | $1.79 | 651,000 | |
| $1.77 | -0.08 | -4.3% | $1.85 | $1.85 | $1.76 | 565,300 | |
| $1.85 | -0.07 | -3.6% | $1.89 | $1.92 | $1.84 | 486,400 | |
| $1.92 | +0.10 | +5.5% | $1.82 | $1.94 | $1.78 | 1,508,300 | |
| $1.82 | -0.01 | -0.5% | $1.82 | $1.835 | $1.78 | 412,700 | |
| $1.83 | -0.06 | -3.2% | $1.90 | $1.91 | $1.80 | 634,500 | |
| $1.89 | +0.035 | +1.9% | $1.84 | $1.919 | $1.835 | 1,061,700 | |
| $1.855 | +0.015 | +0.8% | $1.84 | $1.87 | $1.80 | 657,400 | |
| $1.84 | +0.015 | +0.8% | $1.83 | $1.855 | $1.81 | 291,300 | |
| $1.825 | -0.085 | -4.5% | $1.91 | $1.91 | $1.81 | 447,100 | |
| $1.91 | -0.04 | -2.1% | $1.94 | $1.94 | $1.91 | 252,100 | |
| $1.95 | +0.08 | +4.3% | $1.87 | $1.95 | $1.87 | 1,826,600 | |
| $1.87 | +0.06 | +3.3% | $1.82 | $1.886 | $1.815 | 1,005,400 | |
| $1.81 | +0.03 | +1.7% | $1.79 | $1.83 | $1.75 | 641,900 | |
| $1.78 | +0.01 | +0.6% | $1.795 | $1.805 | $1.77 | 242,700 | |
| $1.77 | -0.08 | -4.3% | $1.84 | $1.85 | $1.755 | 368,400 |
- Ticker
- NASDAQ:ENGN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
Latest deck · Nov 12, 2026
Investor Presentation (November 2026)
Investor deck · 41 slides
Latest news
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
Nov 11, 2026
Closed $2.28 (+26.7%) on Nov 12, 2026
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
Nov 11, 2026
Closed $2.28 (+26.7%) on Nov 12, 2026
enGene to Participate in Upcoming Investor Conferences
Nov 6, 2026
Closed $1.75 (+4.2%) on Nov 6, 2026
enGene to Host KOL Webinar on October 15, 2026
Oct 13, 2026
Closed $1.63 (-4.1%) on Oct 13, 2026
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Sep 8, 2026
Closed $1.92 (+5.5%) on Sep 8, 2026
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Jul 16, 2026
Closed $1.92 (+1.1%) on Jul 16, 2026
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
Jun 15, 2026
Closed $1.77 (+9.3%) on Jun 15, 2026
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
Closed $1.72 (-80.6%) on May 7, 2026
enGene Announces Name Change to enGene Therapeutics Inc.
Apr 7, 2026
Closed $7.33 (+1.2%) on Apr 7, 2026
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Mar 9, 2026
Closed $7.05 (-18.8%) on Mar 9, 2026
enGene Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 61 in all · newest Nov 11, 2026 · oldest 2023
- Decks
- 16 decks · latest Nov 12, 2026
Where enGene Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ENGN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ENGN | BOATS | United States | USD |
| Frankfurt:S0N0 | Frankfurt | Germany | EUR |
Valuation
Price/book 0.5× against a median of 2.6×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- −$149.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.82
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| enGene Therapeutics Inc. · NASDAQ:ENGN | US$116.6M | −US$149.7M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.82 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.4× | n/a | n/a | −146.4% | n/a | n/a |
| STCube, Inc. · KRX:052020 | US$118.4M | US$72.43M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| Curacle Co., Ltd. · KRX:365270 | US$117.6M | US$100.4M | n/a | 16.3× | n/a | 3.4× | −92.1% | 0.0× | n/a |
| PegBio Co., Ltd. Class H · HKEX:2565 | US$117.2M | US$55.97M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.23M | n/a | 59,064× | n/a | 3.6× | n/a | 0.0× | n/a |
| Armata Pharmaceuticals, Inc. · AMEX:ARMP | US$112.7M | US$346.0M | n/a | 45.8× | n/a | n/a | n/a | n/a | 0.97 |
| Medigen Biotechnology Corporation · TPEX:3176 | US$111.8M | US$61.95M | n/a | 1.6× | n/a | 2.5× | −19.9% | 0.8× | n/a |
| Median of the others | US$117.9M | US$67.19M | 13.6× | 2.6× | −188.0% | 0.0× | 0.97 |
Forecasts
4 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.29 USD · Analysts' mean
- EPS, year to Oct 2026
- -1.82 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ron Cooper | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Michael Heffernan | Chairman |
| Ron Cooper | Chief Executive Officer |
| William Grossman | Director |
Events
- Next results
- Dec 28, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Sep 8, 2026 · Before open | +5.5% |
| Q2 2026 | Jun 15, 2026 · Before open | +9.3% |
| Q1 2026 | Mar 9, 2026 | −20.1% |
| Q4 2025 | Dec 22, 2025 · After close | +5.1% |
| Q3 2025 | Sep 11, 2025 · After close | −5.8% |
| Q2 2025 | Jun 12, 2025 · Before open | +0.9% |
| Q1 2025 | Mar 10, 2025 · After close | −1.7% |
| Q4 2024 | Dec 19, 2024 · After close | −2.2% |
| Q3 2024 | Sep 10, 2024 · After close | +3.1% |
| Q2 2024 | Jun 14, 2024 · Before open | −10.0% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Mar 11, 2024 · After close | +1.6% |
| Q4 2023 | Jan 3, 2024 | −22.3% |
| Q2 2023 | Jun 30, 2023 | +0.1% |
| Q1 2023 | Mar 30, 2023 | +0.6% |
| Quarter to Oct 31, 2022 | Nov 10, 2022 | +0.4% |
| Quarter to Jul 31, 2022 | Aug 11, 2022 | −0.2% |
| Quarter to Apr 30, 2022 | May 13, 2022 | −0.8% |
| Quarter to Jan 31, 2022 | Apr 14, 2022 | −0.1% |
| Quarter to Oct 31, 2021 | Jan 24, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 41 slides | Nov 12, 2026 |
| Technical Presentation (November 2026) | Technical | 35 slides | Nov 12, 2026 |
| Technical Presentation (October 2026) | Technical | 35 slides | Oct 15, 2026 |
| Investor Presentation (September 2026) | Investor deck | 37 slides | September 2026 |
| Investor Day (August 2026) | Investor day | 23 slides | Aug 11, 2026 |
| Investor Presentation (July 2026) | Investor deck | 35 slides | Jul 17, 2026 |
| Corporate Update (May 2026) | Corporate update | 20 slides | May 7, 2026 |
| American Urological Association Annual Meeting 2026 | Conference | 12 slides | May 2026 |
| Investor Presentation (November 2025) | Investor deck | 31 slides | Nov 12, 2025 |
| Corporate Update (November 2025) | Corporate update | 15 slides | Nov 12, 2025 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2025) | Investor deck | 28 slides | Sep 3, 2025 |
| Investor Presentation (October 2024) | Investor deck | 28 slides | Oct 25, 2024 |
| Technical Presentation (September 2024) | Technical | 7 slides | Sep 26, 2024 |
| Investor Presentation (September 2024) | Investor deck | 25 slides | Sep 5, 2024 |
| Investor Presentation (June 2024) | Investor deck | 21 slides | Jun 14, 2024 |
| 2024 AUA Annual Meeting | Conference | 12 slides | 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of common shares Announced: Jefferies +2 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Wells Fargo Securities (co-lead) | Nov 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 94.5M | 38.3M | 16.5M | 15.5M |
| Operating income | -123.2M | -62.3M | -26.1M | -19.4M |
| Depreciation and amortization | 500.0K | 300.0K | 200.0K | 200.0K |
| EBITDA | -122.7M | -62.0M | -25.9M | -19.2M |
| Interest expense | 2.99M | 2.80M | 4.95M | 1.42M |
| Income before tax | -117.3M | -55.2M | -99.9M | -24.4M |
| Income tax | 0 | -19.0K | 17.0K | 22.0K |
| Net income | -117.3M | -55.1M | -99.9M | -24.5M |
| Earnings per share, basic | 2.29 | 1.46 | 151.22 | 44.30 |
| Earnings per share, diluted | 2.29 | 1.46 | 151.22 | 44.30 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 50.2M | 173.0M | 81.5M | 20.4M |
| Short-term investments | 143.6M | 65.3M | ||
| Current assets | 201.4M | 247.4M | 85.4M | 22.6M |
| Property, plant and equipment | 2.48M | 1.17M | 589.0K | 387.0K |
| Total assets | 221.5M | 311.2M | 87.0M | 23.9M |
| Accounts payable | 6.69M | 1.41M | 1.16M | 723.0K |
| Current liabilities | 32.0M | 14.7M | 5.26M | 5.10M |
| Total liabilities | 53.8M | 38.6M | 14.5M | 47.4M |
| Shareholders' equity | 167.7M | 272.6M | 72.5M | -76.6M |
| Shares outstanding | 52.0M | 51.0M | 23.2M | 665.8K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -99.2M | -48.3M | -24.7M | -17.6M |
| Capital spending | -1.49M | -925.0K | -318.0K | -153.0K |
| Free cash flow | -100.7M | -49.2M | -25.1M | -17.7M |
| Cash from investing | -25.1M | -126.0M | -318.0K | -153.0K |
| Cash from financing | 1.52M | 265.7M | 86.1M | 28.0M |
| Dividends paid | 0 | |||
| Change in cash | -122.9M | 91.5M | 61.1M | 9.42M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Sep 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 8, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 22, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 16, 2026 | Management or board change | SEC |
| 8-K/A · Current report, amended | Jun 18, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 15, 2026 | Results | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | May 8, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | May 8, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 7, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 9, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Mar 9, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Mar 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Mar 3, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 26, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 25, 2026 | Other filings | SEC |
| S-3 · Registration statement | Feb 19, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Feb 19, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 21, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 21, 2026 | Current report | SEC |
| 10-K · Annual report | Dec 22, 2025 | Annual report | SEC |
| 8-K · Current report | Dec 22, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 8-K · Current report | Oct 2, 2025 | Management or board change | SEC |
| 8-K/A · Current report, amended | Oct 2, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 11, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Sep 11, 2025 | Results | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jun 12, 2025 | Results | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 9, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 4, 2025 | Management or board change | SEC |
| 3 · Initial statement of ownership | May 29, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 9, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 9, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Mar 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Mar 10, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | Feb 20, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 20, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 10-K · Annual report | Dec 19, 2024 | Annual report | SEC |
| 8-K · Current report | Dec 19, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Nov 22, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 22, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 21, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 21, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 18, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 13, 2024 | Offer document | SEC |
| S-3 · Registration statement | Nov 13, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 1, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 28, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 25, 2024 | Material contract | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2024 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 21, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 21, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 21, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 26, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 26, 2024 | Current report | SEC |
| 424B3 · Prospectus | Sep 10, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | Sep 10, 2024 | Results | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Jul 24, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 24, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Jun 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 14, 2024 | Results | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 17, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | May 15, 2024 | Offer document | SEC |
| 8-K · Current report | May 15, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 25, 2024 | Offer document | SEC |
| 4 · Change in ownership | Apr 22, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 18, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 18, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 11, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Mar 11, 2024 | Quarterly report | SEC |
| 8-K · Current report | Mar 11, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Mar 6, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Mar 5, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 4, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 26, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 26, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Feb 26, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 23, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 23, 2024 | Big-stake notice | SEC |
This page holds 200 of 272 filings. Open Filings
Cap table
Built by 6ix from enGene Therapeutics Inc.’s releases · as of Nov 12, 2025
- Common shares
- 67,016,316
- Fully diluted
- 67,466,316
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 67,016,316 |
| Options and RSUs | 450,000 |
Warrants and options
| Lot |
|---|
| Stock options · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 67,016,316 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lota S Zoth Other companies: First Financial Bankshares, Inc. (Director · Since at least Apr 28, 2026); 89bio Inc (Director · Since at least Jun 1, 2020); Inovio Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2019); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 21, 2022 · Past); Spark Therapeutics Inc (CHIEF SCIENTIFIC OFFICER, Director · Jan 6, 2016 – Dec 17, 2019 · Past); Lumos Pharma Inc (Director · Nov 2, 2012 – Dec 12, 2024 · Past); Hyperion Therapeutics Inc (Director · Jul 25, 2012 – May 7, 2015 · Past); Orexigen Therapeutics Inc (Director · Apr 26, 2012 – Jul 14, 2017 · Past); Medimmune Inc (SVP, Chief Financial Officer · Feb 23, 2006 – Jun 18, 2007 · Past) | Director · Since at least Dec 18, 2023 |
| Paul Hastings Other companies: Nkarta, Inc. (Chief Executive Officer, Director · Since at least Jan 4, 2024); Pacira BioSciences, Inc. (Director · Jun 12, 2024 – Jun 12, 2024 · Past) | Director · Since at least May 15, 2024 |
| Philip Astley-Sparke Other companies: Replimune Group, Inc. (Director · Since at least Jul 19, 2018); uniQure N.V. (Director · Jan 26, 2018 – Mar 2, 2021 · Past) | Director · Since at least Jul 8, 2025 |
| Richard Paul Bryce Other companies: Rain Oncology Inc (Chief Medical Officer · Apr 22, 2021 – Feb 15, 2023 · Past); Puma Biotechnology Inc (SEE REMARKS · Jun 20, 2012 – Apr 5, 2021 · Past) | Chief Medical Officer · Oct 31, 2023 – Nov 30, 2023 · Past |
| William Grossman Other companies: Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); Arcus Biosciences, Inc. (Chief Medical Officer · Apr 29, 2019 – Jun 16, 2021 · Past) | Director · Since at least Jul 8, 2025 |
| Wouter Joustra Other companies: Vor Biopharma Inc. (Director · Since at least Dec 18, 2025); NewAmsterdam Pharma Company N.V. (Director · Jul 16, 2024 – Jul 16, 2024 · Past) | Director · Since at least May 15, 2024 |
| Amy Pott Other companies: Wave Life Sciences Ltd. (Director · Sep 4, 2019 – Aug 18, 2020 · Past) | Chief Global Comm. Ofc. · Since at least May 27, 2025 |
| D Ryan Daws Other companies: Concert Pharmaceuticals Inc (Chief Financial Officer · Feb 12, 2014 – Jan 4, 2017 · Past) | Chief Financial Officer · Since at least Nov 27, 2023 |
| Jason David Hanson Other companies: BullFrog AI Holdings, Inc. (Director · Since at least Feb 13, 2023) | Chief Executive Officer, Director · Oct 31, 2023 – Oct 31, 2023 · Past |
| Jasper Bos Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026) | Director · Since at least Oct 31, 2023 |
All 22 people
| Person | Seat |
|---|---|
| Richard Glickman Other companies: ESSA Pharma Inc (Director · Since at least Oct 1, 2020) | Director · Since at least Oct 31, 2023 |
| Alexandre Jean-Rene Erwan Grassin | Int. Chief Financial Officer · Oct 31, 2023 – Oct 31, 2023 · Past |
| Gerald A Brunk | Director · Since at least Oct 31, 2023 |
| Hussein Sweiti | Chief Medical Officer · Sep 30, 2025 – Nov 5, 2026 · Past |
| James Crowley Sullivan | Chief Scientific Officer · Oct 31, 2023 – Oct 31, 2023 · Past |
| Jill Buck | Chief Development Officer · Jul 8, 2025 – Nov 5, 2026 · Past |
| Joan Connolly | Chief Technology Officer · Since at least Oct 21, 2024 |
| Kathleen P Richton | SVP, Finance and Treasurer · Since at least Jul 16, 2026 |
| Lee Giguere | Chief Legal Ofc. and Corp Secy · Since at least Jan 30, 2026 |
| Matthew Ross Boyd | Chief Regulatory Officer · Since at least Jul 8, 2025 |
| Michael Heffernan | Chairman · Since at least Sep 8, 2026 |
| Ron Cooper | Chief Executive Officer · Since at least Sep 8, 2026 |
Log in to ask 6ix AI your own questions about enGene Therapeutics Inc.